Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer

Vince Kornél Grolmusz1,2, Katalin Karászi3, Tamás Micsik3, Eszter Angéla Tóth4, Katalin Mészáros2,5, Gellért Karvaly2,5,6, Gábor Barna3, Péter Márton Szabó7, Kornélia Baghy3, János Matkó8, Ilona Kovácszky3, Miklós Tóth9, Károly Ráczi1,7, Péter Igaz1, Attília Patócs1,5,6

12nd Department of Medicine, Semmelweis University, Budapest, Hungary; 2nd Hereditary Endocrine Tumours Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary; 3nd Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; 4th Department of Immunology, Eötvös Loránd University, Budapest, Hungary; 5th Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary; 6th Bionics Innovation Center, Budapest, Hungary; 7th Molecular Medicine Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary

Received May 30, 2016; Accepted June 6, 2016; Epub September 1, 2016; Published September 15, 2016

Abstract: Adrenocortical cancer (ACC) is a rare, but aggressive malignancy with poor prognosis. Histopathological diagnosis is challenging and pharmacological options for treatment are limited. By the comparative reanalysis of the transcriptional malignancy signature with the cell cycle dependent transcriptional program of ACC, we aimed to identify novel biomarkers which may be used in the histopathological diagnosis and for the prediction of therapeutic response of ACC. Comparative reanalysis of publicly available microarray datasets included three earlier studies comparing transcriptional differences between ACC and benign adrenocortical adenoma (ACA) and one study presenting the cell cycle dependent gene expressional program of human ACC cell line NCI-H295R. Immunohistochemical analysis was performed on ACC samples. In vitro effects of antineoplastic drugs including gemcitabine, mitotane and 9-cis-retinoic acid alone and in combination were tested in the NCI-H295R adrenocortical cell line. Upon the comparative reanalysis, ribonucleotide reductase subunit 2 (RRM2), responsible for the ribonucleotide deoxyribonucleotide conversion during the S phase of the cell cycle has been validated as cell cycle dependently expressed. Moreover, its expression was associated with the malignancy signature, as well. Immunohistochemical analysis of RRM2 revealed a strong correlation with Ki67 index in ACC. Among the antiproliferative effects of the investigated compounds, gemcitabine showed a strong inhibition of proliferation and an increase of apoptotic events. Additionally, RRM2 has been upregulated upon gemcitabine treatment. Upon our results, RRM2 might be used as a proliferation marker in ACC. RRM2 upregulation upon gemcitabine treatment might contribute to an emerging chemoresistance against gemcitabine, which is in line with its limited therapeutical efficacy in ACC, and which should be overcome for successful clinical applications.

Keywords: Fluorescence activated cell sorting (FACS), adrenocortical cancer (ACC), ribonucleotide reductase, ribonucleotide reductase subunit 2 (RRM2), cell cycle, cell cycle-dependent, malignancy signature, proliferation marker, gemcitabine-resistance, chemoresistance

Introduction

Adrenocortical cancer (ACC) is a rare, but highly aggressive malignancy with poor prognosis [1], with annual incidence varying between 0.7 to 2.0 cases per million population [1, 2]. Although surgical removal in the case of strictly localized tumors might result in favourable outcome, overall 5-year survival rate remains poor at only 22-37% [3, 4]. Pharmacological options are limited mostly to the use of the adrenolytic agent mitotane [1], therefore, the applicability of various other drugs frequently used in advanced stage is under investigations [1, 5-9]. Novel pharmacological targets are needed, although, due to the rarity of the disease, prospective, controlled trials of novel drugs are challenging [1].
The two most frequently altered molecular pathways in adrenocortical tumorigenesis are Wnt/β-catenin and IGF-2 signaling pathways [1]. Pharmacological targeting of IGF signaling resulted in a marked decrease in proliferation [10] and it potentiated the effect of simultaneously administered mitotane [10]. Additionally, blocking of intrinsically produced IGF-2 increased the antiproliferative effect of mTOR inhibitor sirolimus on ACC cell line [11]. In contrast with these promising in vitro data, the small molecular IGF1-receptor inhibitor linistinib turned out to be ineffective in a recent clinical trial [12].

In search of potential new targets in ACC, gene expression comparison between ACCs and benign adrenocortical adenomas (ACA) is of the utmost importance. Hundreds of genes are upregulated in ACC’s malignancy signature, the gene expression hallmark differentiating malignant neoplasms (ACC) from benign lesions (ACA) [13-15]. Among these, several genes may represent promising targets for further therapies. Upon a complex bioinformatics analysis, we previously identified (i) cell cycle, (ii) retinoic acid signaling and (iii) complement system and antigen presentation as the three major pathogenic pathways of adrenocortical tumorigenesis [16]. In addition, our group confirmed the antiproliferative effect of 9-cis retinoic acid in ACC in vitro and in vivo [7, 9].

During the cell cycle, several key agents display cell cycle dependent expression on mRNA and protein level [17]. Alternatively, post-transcriptional modifications of certain proteins harbor specific role for the proper maintenance of cell cycle progression [17]. Inhibiting key regulators of the cell cycle machinery might decelerate cell cycle progression. Therefore, large emphasis was dedicated to create novel drugs targeting specific cell cycle regulators being tested in different clinical trials [18].

Detecting cell cycle dependent expression in unperturbed cells is challenging [19, 20]. Synchronization based techniques, followed by time-course gene expression profiling have been widely used to detect the cell cycle dependent transcription program [20-22]. However, synchronization procedures result in growth imbalance and alteration of the cell cycle machinery [23-25]. We previously showed that DNA content based fluorescence activated cell sorting (cell cycle sort) is able to discriminate cell cycle phases without perturbing the cell cycle machinery [25]. High-throughput profiling of mRNA and miRNA transcripts revealed the cell cycle dependent transcriptional profile in the ACC cell line NCI-H295R [25].

Here, by the reanalysis of the previously described gene expression profiles measured in ACC and ACA samples and comparing with the cell cycle dependent transcription profile of NCI-H295R cell line, we identified ribonucleotide reductase subunit M2 (RRM2) as a cell cycle dependently expressed gene overexpressed in ACC compared to ACA. Moreover, expression level of the RRM2 protein correlated well with Ki67 labeling index in ACC samples, therefore, its expression may be used as a novel proliferation marker in ACC with a possibility of contributing to prognostic information upon histopathological diagnosis. Additionally, antiproliferative effect, in particular with regard to RRM2 expression, of gemcitabine (G), mitotane (M), 9-cis-retinoic acid (R) (the former targeting cell cycle progression specifically on RRM2) and their combinations on ACC cell line NCI-H295R were studied. Although significant reduction in proliferative activity of various drugs have been shown, RRM2 has been upregulated upon gemcitabine treatment. This upregulation implies an emerging chemoresistance against gemcitabine [26, 27], resulting in limited antiproliferative effect in patients with ACC observed earlier [5, 8].

Materials and methods

Reanalysis of publicly available microarray data

For the comparison of the cell cycle dependent transcripts with the malignancy signature of ACC, data from three previous microarray studies [13-15] examining gene expression alterations between ACC and ACA tissues were downloaded from the European Bioinformatics Institute Array Express database (accession number: E-TABM-311) and from National Center for Biotechnology Information’s Gene Expression Omnibus (accession numbers: GSE10927 and GSE14922), and were reanalyzed. In total, one hundred fifty-four microarray data (ACA = 87; ACC = 67) were studied. Cell cycle dependent expression profile of ACC cell line NCI-H295R, previously established by our research group...
RRM2 in adrenocortical cancer

[25], was downloaded from National Center for Biotechnology Information’s Gene Expression Omnibus (accession number: GSE73256). Significant gene expression alterations between ACC vs. ACA and S vs. G1 phase exceeding two-fold change were compared.

**Cell culture and treatments**

Human adrenocortical cancer cell line NCI-H295R was obtained from the American Type Culture Collection (ATCC). NCI-H295R cells were cultured in Dulbecco's modified Eagle's medium/Nutrient Mixture F-12 Ham (DMEM:F12) supplemented with 6.25 ng/ml insulin, 6.25 ng/ml transferrin, 6.25 ng/ml sodium selenite, 1.25 mg/ml bovine serum albumine, 5.35 ng/ml linoleic acid, 1% HEPES, 1% Penicillin-Streptomycin, 2.5% L-glutamine (Sigma-Aldrich Chemical Co.) and 2.5% Nu-Serum (BD Biosciences), as previously reported [25]. Cells were cultured at 37°C in a humidified 5% CO2 atmosphere.

For different treatments, 5×10^5 cells were plated in each well of a 6-well plate (for subsequent flow cytometry, gene and protein expression studies) or 1×10^6 cells were plated in each well of a 96-well plate (for subsequent proliferation assay). After 24 h, eight treatment regimens of gemcitabine (G, G6423, Sigma-Aldrich Chemical Co.), mitotane (M, N12706, Sigma-Aldrich Chemical Co.) and 9-cis-retinoic acid (R, sc-205589A, Santa Cruz Biotechnology) were introduced: control, G, M, R, G+M, G+R, M+R, G+M+R. Drugs were resolved in DMSO and were added in the optimal concentrations of 5×10^-6 mol/dm^3 (G and M) or 5×10^-5 mol/dm^3 (R), as previously proposed [6, 7, 28]. Equal volume of 4 μL of DMSO vehicle was added to control samples as well. Thereafter, samples were collected 24 h, 48 h and 72 h after treatments began.

**Flow cytometry analysis**

DNA content based fluorescence activated cell sorting (cell cycle sort) was performed as described previously [25]. Sorted cells to G1, S and G2 phases were reanalyzed, centrifuged, washed with ice-cold PBS and resuspended in QIAzol lysis reagent (Qiagen) or Western blot lysis buffer for subsequent RNA and protein isolation. Until RNA isolation or Western blot, samples were stored at -80°C [25].

For apoptosis and cell cycle distribution detection upon different treatments, cells were trypsinized, washed and centrifuged for 5 minutes at 1000 rpm. The supernatant was discarded, cells were resuspended in ice-cold 70% ethanol and incubated at room temperature for 20 minutes. Thereafter, cells were stored at -20°C for 30 minutes and cells were centrifuged for 5 minutes at 1000 rpm. The supernatant was discarded and cells were resuspended in a 100 ng/ml RNase containing extraction buffer (200 mmol/l NaHPO4, pH = 7.8) and incubated at room temperature for 15 minutes. Then, propidium iodide was added to a final concentration of 10 ng/ml and cells were incubated for another 15 minutes. Thereafter, samples were measured by a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). At least 10,000 events were collected. Data were analyzed by Cell Quest Pro and Winlist softwares.

**Cortisol measurements in NCI-H295R cell supernatants after various treatments**

After treatments, cell culture medium was aspirated, centrifuged for 10 minutes at 1000 rpm and the supernatants were stored at -80°C until steroid measurements.

For the liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, the external (cortisol solution 1 mg/ml in methanol) and the internal standard (cortisol-9, 11, 12, 12-D4 solution 100 µg/ml in methanol), both certified reference materials, were purchased from Sigma-Aldrich Hungary Ltd (Budapest, Hungary). LC-MS grade water, LC-MS grade methanol and LC-MS grade formic acid 85% were procured from VWR International Ltd (Debrecen, Hungary).

Sample preparation was based on protein precipitation. 5 µl internal standard (concentration 1 µg/ml) was added to 245 µl sample. 750 µl acetonitrile was then added to this mix and after vortexing it was centrifuged 5 minutes at 13500 rpm. The supernatant was diluted in 1:1 proportion with MS grade water.

LC-MS/MS assays were performed on a Perkin-Elmer Flexar FX10 ultra-performance liquid chromatograph coupled to a Sciex 5500QTRAP mass spectrometer (Per-Form Hungária Kft, Budapest, Hungary). For chromatographic separation we used a Phenomenex Kinetex XB-C18 stationary phase (50×2.1 mm, 1.7 µm) attached...
to a 2×4.6 mm Phenomenex SecurityGuard Ultra C18 guard column (Gen-Lab Kft, Budapest, Hungary) and kept at 35°C. The mobile phase consisted of water containing 0.1% formic acid (A) and methanol containing 0.1% formic acid (B). The following gradient program was used: 10% B, hold 1.5 minutes, ramp B to 90% in 2 minutes, hold 1.5 minutes, ramp B to 10% in 0.5 minutes, hold 1.5 minutes (total run time: 7 minutes). The eluent flow rate was 200 µl/min and the injection volume was 20 µl.

The mass spectrometer was operated in negative electrospray ionization mode with the following settings. Source temperature: 350°C, ionization voltage: -4500 V, curtain gas: 35 psi, gas 1: 35 psi, gas 2: 35 psi, entrance potential: -10 V.


**Proliferation assay**

The effect on cell proliferation of certain drug combinations was measured using alamarBlue cell proliferation reagent (DAL1025, Thermo Fischer Scientific). At time points 0 h, 24 h, 48 h and 72 h, 10 µl of AlamarBlue reagent was added to the culture medium. After 180 minutes incubation at 37°C in a humidified 5% CO₂ atmosphere, fluorescence measurement was performed on Varioskan Flash spectral scanning reader (Thermo Fisher Scientific). Excitation and emission maxima were 560 and 590 nms, respectively. Acquired data at each time point were normalized to the fluorescence detected at 0 h at the same well.

**RNA isolation and quantitative real-time PCR**

For RNA isolation, samples were collected after successful cell cycle sort or at 24 h, 48 h, 72 h of the drug treatments. Cells were washed with ice-cold PBS, resuspended in Qiazol lysis reagent (Qiagen) and stored at -80°C until RNA isolation. Total RNA was isolated with miRNeasy Mini Kit (Qiagen), according to the manufacturer’s instructions. RNA concentration was determined by NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). Total RNA was reverse transcribed with SuperScript VILO cDNA synthesis kit according to the manufacturer’s instructions (Thermo Fisher Scientific). Gene expression was quantified using predesigned TaqMan gene expression assays (probe IDs: RRM2: Hs00357247_g1, ACTB: Hs99999903_m1) on a 7500 Fast Real-time PCR system (Thermo Fisher Scientific). ACTB was used as internal control.

All measurements were performed in triplicate (three biological, two technical replicates). Expression level was calculated by the ΔΔCt method.

**Protein isolation and immunoblotting**

Protein isolation, concentration measurements and Western blot analysis was performed as earlier reported [25]. Primary antibody dilutions were 1:200 for anti-RRM2 antibody (cat. No.: sc-10846, Santa Cruz Biotechnology) and 1:2000 for anti-β-actin antibody (cat. No.: 4967, Cell Signaling Technology). β-actin was used as loading control.

**Immunohistochemistry**

Formalin-fixed paraffin-embedded tissue sections of twelve ACCs were formerly diagnosed.
histopathologically at the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University and were chosen for immunohistochemical analysis. The main demographic data of patients studied is summarized in Table 1. 4 µm-thick sections were cut, then mounted on SuperFrost/Plus slides and stored at 4°C until the staining. For RRM2 staining the non-specific binding was blocked with 5% bovine serum albumin (BSA, 20 minutes, RT). The endogenous biotin, biotin receptors and avidin binding sites in tissues were blocked (15-15 minutes, RT) with the avidin/biotin blocking kit (Vector laboratories, SP-2001). Goat polyclonal anti-RRM2 (sc-10846, Santa Cruz Biotechnology) was used at 1:100 (overnight, 4°C). Biotinylated polyclonal rabbit anti-goat immunoglobulin (Dako Cytomation, E0466) was applied at 1:200 dilution for 1 h at RT. Sensitivity was enhanced with VECTASTAIN Elite ABC Kit (Standard, PK-6100, Vector Lab.) and staining was visualized with DAB Chromogen Kit (Biocare Medical, DB801R) for 10 minutes. Slides were counterstained with haematoxylin. The primary antibody was omitted in negative controls.

Evaluation of immunostainings

The stained slides were digitally scanned with a high-resolution scanner (Pannoramic Scan, 3DHISTECH Ltd.), and used for virtual microscopic evaluation with the Pannoramic Viewer 1.15 (3DHISTECH Ltd.). Ki67 and RRM2 stainings were scored independently in a blinded manner by 3 observers (VKG, KK and TM). Ki67 index was determined as the portion of positive cells upon examining 1000 cells. RRM2 score was determined as described earlier [29]. It was based on staining intensity of individual cells (0 = none, 1 = weak, 2 = moderate, 3 = strong) and the portion (0-100%) of cells staining at each intensity level [29]. RRM2 score was calculated by the RRM2 score = 1x+2y+3z method, where x, y, z are the percentage of cells with weak (x), moderate (y) and strong (z) immunoreactivity [29]. Modified Weiss score [30] was determined by a pathologist specialized in adrenal pathology (TM).

Statistical analysis

For detecting differently expressed mRNA transcripts, Students’ two sided independent samples T-test was used. Upon ΔCt values, differences were analyzed between G1 vs. S, S vs. G2 and G1 vs. G2 phases (cell cycle experiment).
RRM2 in adrenocortical cancer

**Table 2.** List of genes displayed in the overlap of the Venn diagram (Figure 1A)

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Fold change (ACC vs. ACA)</th>
<th>Fold change S vs. G1 phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>RRM2</td>
<td>5.245</td>
<td>9.164</td>
</tr>
<tr>
<td>HJURP</td>
<td>12.662</td>
<td>9.586</td>
</tr>
<tr>
<td>SPC24</td>
<td>2.709</td>
<td>8.543</td>
</tr>
<tr>
<td>WDR62</td>
<td>7.382</td>
<td>9.586</td>
</tr>
<tr>
<td>CDC2</td>
<td>3.084</td>
<td>13.485</td>
</tr>
<tr>
<td>SKA1</td>
<td>3.949</td>
<td>7.462</td>
</tr>
<tr>
<td>GTSE1</td>
<td>2.671</td>
<td>3.114</td>
</tr>
<tr>
<td>STIL</td>
<td>3.466</td>
<td>11.213</td>
</tr>
<tr>
<td>ASPM</td>
<td>4.593</td>
<td>28.779</td>
</tr>
<tr>
<td>IQGAP3</td>
<td>5.426</td>
<td>12.662</td>
</tr>
<tr>
<td>ARHGAP11A</td>
<td>8.580</td>
<td>5.502</td>
</tr>
<tr>
<td>PLK4</td>
<td>2.201</td>
<td>8.537</td>
</tr>
<tr>
<td>CDK2</td>
<td>4.031</td>
<td>10.458</td>
</tr>
<tr>
<td>COL1A1</td>
<td>2.680</td>
<td>2.680</td>
</tr>
<tr>
<td>HOXB13</td>
<td>3.420</td>
<td>3.415</td>
</tr>
</tbody>
</table>

List of genes altered in ACC vs. ACA and S vs. G1 phase as well. In all comparisons significant (p-value < 0.05) alterations of at least two-fold change in expression are presented. Lacking values represent nonsignificant alterations or significant alterations below two-fold change in expression.

Expression of RRM2 is cell cycle dependent in ACC cell line NCI-H295R

Successful validation of cell cycle dependent expression of RRM2 in ACC cell line NCI-H295R was performed on cell cycle sorted samples (Figure 1B and 1C). As reported previously in other cells [31], RRM2 expression rises in S phase, acquiring an important role in the creation of the ribonucleotide reductase complex.

**RRM2 correlates well with Ki67 index in ACC**

Upon immunohistochemical analysis of RRM2 and Ki67 in 12 selected ACC samples of various proliferative activity (Table 1), RRM2 expression was found to be tightly correlated with the widely used proliferation marker Ki67 index (Figure 2).

**Effects of different drug treatments on the proliferation, apoptosis, cortisol production and cell cycle distribution of NCI-H295R cells**

Although all treatment regimens decreased proliferation of ACC cells after 72 h, cells treated with G alone or in combination showed the largest decrease in proliferation compared to other treatments (Figure 3A). Additionally, G-mediated decrease in proliferation was detectable at shorter treatment times as well. Higher concentration and treated vs. control groups (drug treatment experiment).

For detecting correlation between Ki67 index and RRM2 score, Spearman’s nonparametric correlation was used.

For detecting differences between drug-treated compared to untreated control groups at each time point in relative proliferation rate, cortisol concentration, apoptosis and cell cycle distribution, Students’ two sided independent samples T-test was used.

In all comparisons p-value < 0.05 was considered statistically significant.

**Results**

**Overlap between cell cycle dependent transcription program and the malignancy signature of ACC**

Upon the average of the three microarray studies, 1752 transcripts had a minimum of two-fold change alteration between ACC and ACA, while 29 transcripts showed a minimum of two-fold change alteration between S and G1 phase in ACC cell line NCI-H295R (Figure 1A). 18 transcripts were altered in both the malignancy signature and in the cell cycle (Table 2). Among them, RRM2 had the largest upregulation in S compared to G1 phase. Additionally, RRM2 was significantly upregulated in ACC compared to ACA in all three microarray studies (ASPM was the other gene universally upregulated in all three microarray studies comparing ACCs with ACAs and upregulated in S phase compared to G1 phase as well). Upon these results, RRM2 was chosen for further examination.

Expression of RRM2 is cell cycle dependent in ACC cell line NCI-H295R

Successful validation of cell cycle dependent expression of RRM2 in ACC cell line NCI-H295R was performed on cell cycle sorted samples (Figure 1B and 1C). As reported previously in other cells [31], RRM2 expression rises in S phase, acquiring an important role in the creation of the ribonucleotide reductase complex.

**RRM2 correlates well with Ki67 index in ACC**

Upon immunohistochemical analysis of RRM2 and Ki67 in 12 selected ACC samples of various proliferative activity (Table 1), RRM2 expression was found to be tightly correlated with the widely used proliferation marker Ki67 index (Figure 2).

**Effects of different drug treatments on the proliferation, apoptosis, cortisol production and cell cycle distribution of NCI-H295R cells**

Although all treatment regimens decreased proliferation of ACC cells after 72 h, cells treated with G alone or in combination showed the largest decrease in proliferation compared to other treatments (Figure 3A). Additionally, G-mediated decrease in proliferation was detectable at shorter treatment times as well. Higher
rates of apoptotic cells, in particular after 72 h of treatment with G alone or in combination contributed to the observed decrease in proliferation (Figure 3B). Although M treatment inhibited cortisol production as expected, G treatment had no effect on cortisol production (Figure 3C). Moreover, effects on cell cycle distribution showed a larger portion of G1 phase cells upon G treatment. However, 24 h M and R treatments and especially their combination resulted in a larger portion of G2 phase cells (Figure 3D-F).
RRM2 expression is upregulated upon gemcitabine treatment in NCI-H295R cells

Independently from treatment duration, RRM2 was found to be upregulated upon G treatment by three-fold. Combination with other drugs did not alter G’s effect. Conversely, M and R had no effect on RRM2 expression (Figure 4A). Western blot analysis confirmed the G-mediated alterations on protein level (Figure 4B).

Discussion

Targeting the altered cell cycle machinery in cancers resulted in novel pharmacological agents with confirmed antiproliferative impact [18]. However, different, cell type-specific driver genes contribute to the accelerated cell cycle in various cancers. Therefore, novel cancer-specific target genes are needed for the development of novel, effective and targeted chemotherapeutic approaches.

The only adrenal cortex specific drug is mitotane [1], whereas several other cytostatic compounds are administered mostly in advanced stages of ACC with moderate efficacy [1, 5-8]. Due to its rarity, clinical trials that might result in evidence-based recommendations in ACC are limited [1].

In this study, by comparing the cell cycle dependent transcription program with the malignancy signature of ACC, we aimed to detect novel proliferation markers, which may facilitate the rather challenging histopathological diagnosis of ACC [32]. Additionally, by detecting cell cycle dependently expressed genes overexpressed in the malignancy signature as well, new pharmacological targets of ACC had been identified.

More than 60% of cell cycle regulated genes in NCI-H295R cells were dysregulated in the
RRM2 in adrenocortical cancer

Figure 4. RRM2 expression upon different treatments in NCI-H295R cells. A: qRT-PCR measurements of RRM2 upon different treatments. ΔCt value was normalized to RRM2 expression in 24 h control samples (ΔΔCt) and was subjected to FC = 2△Ct transformation. Error bars show standard deviation. Asterisks mark statistical significance (P<0.05). B: Western blot analysis of RRM2 expression after 48 h treatment. β-actin was used as loading control. C control, G gemcitabine, M mitotane, R 9-cis-retinoic acid.

malignancy signature as well. This significant overlap is the consequence of phase-dependent and phase-independent overexpression of cell cycle genes [22, 25]. Phase-dependent overexpression arise from the larger portion of cells being in S and G2 phases in cancer vs. benign cells [22], while phase-independent overexpression is the consequence of basally higher expression of cell cycle genes in cancer cells independently from cell cycle phase [25]. Among genes overexpressed in S vs. G1 phase and in the malignancy signature as well, ribonucleotide subunit M2 (RRM2) had the largest upregulation in S vs. G1 and was also detected as a part of the malignancy signature by all three microarray studies [13-15]. ASPM was the other gene with cell cycle dependent expression manner being present in the malignancy signature by all three microarray studies [13-15].

While abnormal forms of ASPM (abnormal spindle-like microcephaly-associated) gene have been associated with autosomal recessive primary microcephaly [33], overexpression of this proliferative gene has been detected in various cancers [13-15, 34, 35]. Rapid ASPM expression changes upon adjuvant aromatase-inhibitor therapy were found to have important predictive value for response to endocrine therapy in breast cancer [34]. Additionally, by the analysis of oncogenic signaling networks in glioblastoma, ASPM was identified as a key molecular target downstream from mutant epidermal growth factor receptor, which might be inhibited by the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib [35]. Erlotinib, however, only had limited clinical effect in the salvage therapy of ACC [8], although the salvage therapy was initiated only in patients with progressive ACC after two to four previous systemic therapeutic approaches [8].

We evaluated the expression of RRM2 in ACC samples and performed an in vitro study in the human adrenocortical cell line (NCI-H295R) in order to analyze whether the expression of RRM2 might predict the therapeutical response of different antineoplastic drugs used in the treatment of ACC. RRM2 is a subunit of the ribonucleotide reductase complex (RR), which catalyzes the formation of deoxyribonucleotides from ribonucleotides [36]. The enzyme acquires an important role in regulating the total rate of DNA synthesis [37] and its’ activity is strictly regulated during the cell cycle [31, 38]. The short half life of RRM2 is an important factor contributing to the dynamic upregulation of the enzyme activity during S phase [38].

As we identified RRM2 a cell cycle dependently expressed gene in ACC cell line NCI-H295R, also being a contributor to the malignancy signature of ACC, we aimed to analyze its expression in ACC samples, in particular with regard to Ki67 index. Our hypothesis was that, due to its cell cycle-specific expression, it may correlate well with Ki67 index and, therefore, it may be an additional molecular biomarker of proliferation in the histopathological analysis of ACC. Although in a limited sample size, RRM2 score
RRM2 in adrenocortical cancer

[29] showed strong correlation with Ki67 index, therefore, upon a larger scale validation, it may be used in the determination of proliferative status of ACCs, as well. RRM2’s role as a biomarker of proliferation has been confirmed in colorectal [39, 40], breast [41, 42], non-small cell lung [29] and hepatocellular [43] cancer predicting poor survival [29, 40, 42]. Moreover, it has been identified as an important molecular target in anticancer therapy [41, 42].

As RRM2 expression is a hallmark of ACC’s proliferative nature, we aimed to analyze whether its expression decreases upon different treatment regimens in ACC cell line NCI-H295R. Due to their proven antiproliferative effects, mitotane (M) [28], 9-cis-retinoic-acid (R) [7, 9], gemcitabine (G) [6] and their simultaneous combinations were chosen in our in vitro study. Additionally, G has earlier been shown to specifically target RR complex [44], therefore, it became especially important for us to assess RRM2 expression upon G treatment. Although all treatment regimens resulted in a decrease of proliferation, G was the most efficient reaching significant and more robust decrease at an earlier timepoint. However, this correlated with the observed cytotoxic, in particular apoptotic events upon G treatment [6]. Interestingly, G did not alter steroid hormone production, although the administration of M showed the well-known adrenolytic consequence [28]. Assessment of cell cycle distribution confirmed the early S phase block of G, resulting in a larger portion of cells residing in G1 phase. Additionally, results of M and R treatments are also in line with earlier studies characterizing G2 arrest upon M treatment [45, 46] and alteration of the cell cycle upon R treatment [7]. It seems, that simultaneous delivery of M and R synergistically results in rapid G2 arrest, with nearly 30% of cells residing in G2/M phase.

Interestingly, however, G treatment alone as well as in combinations resulted in a time-independent three-fold increase in RRM2 expression, detectable also on protein level, while other treatments did not have any effect on RRM2 expression. Therefore, contrary to the expectations based on the changes in cell cycle distribution [22], a robust, phase-independent up-regulation of RRM2 occurred. This result is in line with the up-regulation of RR-subunit RRM1 upon G treatment in NCI-H295R cells [6]. As higher levels of RRM1 at the initiation of gemcitabine therapy predict poorer efficacy in biliary tract carcinoma [47], and siRNA- or miRNA-mediated silencing of RRM2 restores gemcitabine chemosensitivity in pancreatic cancer [48, 49], we hypothesize, that RRM2 upregulation upon G treatment in ACC cells is the consequence of an emerging chemoresistance against G. This may contribute to the limited effect of G in the therapy of ACC [8]. SiRNA-mediated silencing or inhibition of de novo RRM2 production might as well optimize G treatment in ACC.

In conclusion, by the re-analysis of the malignancy signature and the cell cycle dependent transcription program of ACC, RRM2 had been identified as a key proliferative gene and a potential novel molecular target in ACC. As an immunohistochemical marker, RRM2 might be used to assess the proliferative nature of ACC, therefore, it may be helpful in the diagnosis of borderline lesions. Our in vitro study demonstrated that gemcitabine had a robust effect on proliferation and apoptosis, however, RRM2 upregulation upon gemcitabine treatment may contribute to an emerging chemoresistance against gemcitabine, which should be overcome for successful further clinical applications.

Acknowledgements

This work was supported by the Hungarian Academy of Sciences “Lendület” grant awarded to Attila Patócs (Lendület 2013), by the Hungarian Scientific Research Fund (OTKA, PD100648 (AP)) and by the Technology Innovation Fund, National Developmental Agency (KTIA-AIK-2012-12-1-0010).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Attila Patócs, “Lendület” Hereditary Endocrine Tumours Research Group, Hungarian Academy of Sciences, Semmelweis University, 46 Szentkirályi H-1088 Budapest, Hungary. Tel: +36-1-4591500; Fax: +36-1-2674927; E-mail: patocs.attila@med.semmelweis-univ.hu

References

RRM2 in adrenocortical cancer


